Systemic sclerosis (scleroderma) is an autoimmune disease characterised by pathologic fibrosis of skin and internal organs (lungs, heart, kidneys), driven by activated fibroblasts that overproduce collagen and other extracellular matrix proteins.
Systemic sclerosis (scleroderma) is an autoimmune disease characterised by pathologic fibrosis of skin and internal organs (lungs, heart, kidneys), driven by activated fibroblasts that overproduce collagen and other extracellular matrix proteins. The underlying immunological dysfunction involves autoreactive T cells, B cells producing pathogenic antibodies (anti-topoisomerase, anti-centromere), and dysregulated cytokine signalling (TGF-β, IL-6). Placental MSCs are being explored as an anti-inflammatory and immunomodulatory intervention, delivering cytokines and cell-surface molecules that suppress autoreactive immune cells and potentially reprogram fibroblast behaviour. Unlike conventional disease-modifying antirheumatic drugs (DMARDs), cell therapy aims to reset immune tolerance rather than merely suppress inflammation. Note: autologous haematopoietic stem-cell transplantation (HSCT) is an established, though intensive, option for severe early-stage systemic sclerosis in selected candidates, with demonstrated benefit in some clinical series.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €20,000–€27,500 (dvcstem.com) |
| Main cell types studied | MSCs from Amniotic Membrane |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 42 · 7 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Forty-two completed trials and 7 currently recruiting trials are registered for systemic sclerosis, with diverse cell sources (placental MSC predominating, alongside autologous bone-marrow-derived MSC and HSCT). HSCT trials have shown arrest or reversal of skin fibrosis in approximately 70–80% of treated patients, with sustained benefit at 5-year follow-up in many, though the treatment carries significant morbidity (infection risk, infertility, relapse). MSC trials are smaller and earlier-stage; published data show stabilisation of skin thickening (modified Rodnan skin score stability or improvement) in 50–70% of placental MSC-treated participants over 6–24 months, often accompanied by improved lung function and hand mobility.
Depending on assessment, a Scleroderma (Systemic Sclerosis) protocol may draw on:
Placental MSC infusion for scleroderma costs €5,000–8,500 per treatment course, with many protocols involving two to three infusions spaced weeks to months apart. Autologous HSCT is substantially more expensive (€35,000–60,000), reflecting hospitalisation, high-dose chemotherapy conditioning, stem-cell mobilisation and reinfusion, and intensive post-transplant monitoring. Baseline assessments (skin biopsy, pulmonary function, cardiac imaging) add €2,000–3,500. Long-term immunosuppression post-HSCT incurs ongoing medication costs.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Scleroderma (Systemic Sclerosis) cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Scleroderma (Systemic Sclerosis).
Full Scleroderma (Systemic Sclerosis) FAQ → · Scleroderma (Systemic Sclerosis) cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung